{"content":"<li class=\"n-box-item date-title\" data-end=\"1490068799\" data-start=\"1489982400\" data-txt=\"Sunday, December 22, 2019\">Monday, March 20, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3252348\" data-ts=\"1490054193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHEN\" target=\"_blank\">SHEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252348-shentel-up-4_6-after-breaking-even-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shentel up 4.6% after breaking even in Q4</a></h4><ul>   <li>Shenandoah Telecommunications (NASDAQ:<a href='https://seekingalpha.com/symbol/SHEN' title='Shenandoah Telecommunications Co'>SHEN</a>) <font color='green'>picked up 4.6%</font> after today's <a href=\"https://seekingalpha.com/news/3252187-shenandoah-beats-0_06-misses-revenue\" target=\"_blank\">Q4 earnings</a> came in at break-even vs. an expected loss and revenues rose in every segment.</li>    <li>Revenue grew by 78% thanks to the company's acquisition of nTelos, which boosted wireless, but missed expectations slightly nonetheless.</li>    <li>Wireless postpaid net adds came to 3,777, bringing its total to 722,562. For the full year, taking into account the 404,965 postpaid customers it got in the nTelos transaction last May 6, it added 5,085 net postpaid subs. Postpaid churn in Q4 was 2.1% for the total company (1.6% in Legacy).</li>    <li>At year-end, the company had 236,138 prepaid wireless customers, down 39,308 (affected by a one-time change in counting inactive customers that had an impact of 24,348 removals).</li>    <li><a href=\"https://seekingalpha.com/pr/16775534-shenandoah-telecommunications-company-reports-fourth-quarter-2016-revenue-increased-155_6\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252348\" data-linked=\"Shentel up 4.6% after breaking even in Q4\" data-tweet=\"$SHEN - Shentel up 4.6% after breaking even in Q4 https://seekingalpha.com/news/3252348-shentel-up-4_6-after-breaking-even-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3252348-shentel-up-4_6-after-breaking-even-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252347\" data-ts=\"1490053420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTT\" target=\"_blank\">WTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252347-wireless-telecomminus-5_1-swings-to-q4-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wireless Telecom -5.1% as it swings to Q4 loss</a></h4><ul>   <li>Wireless Telecom Group (<a href='https://seekingalpha.com/symbol/WTT' title='Wireless Telecom Group, Inc'>WTT</a> <font color='red'>-8.1%</font>) is <font color='red'>off 5.1%</font> after hours following <a href=\"https://seekingalpha.com/news/3252329-wireless-telecom-reports-q4-results\" target=\"_blank\">Q4 earnings</a> that wrapped a \"challenging\" year with a swing to a loss.</li>    <li>Revenues rose 14% and the company posted a net loss of $1.16M, vs. year-ago net income of $24,000.</li>    <li>Adjusted EBITDA was -$278,000, vs. a year-ago positive $278,000.</li>    <li>Backlog (orders to be shipping in coming 12 months) was up to $4M from the prior year's $2.5M.</li>    <li>For the coming quarter, the company's guiding to revenue from its combined Network Solutions and Test &amp; Measurement segments of $8M-$8.5M, gross margins of 45-46%, and non-GAAP opex between $3.6M and $3.8M.</li>    <li><a href=\"https://seekingalpha.com/pr/16776167-wireless-telecom-group-announces-fourth-quarter-year-end-2016-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252347\" data-linked=\"Wireless Telecom -5.1% as it swings to Q4 loss\" data-tweet=\"$WTT - Wireless Telecom -5.1% as it swings to Q4 loss https://seekingalpha.com/news/3252347-wireless-telecomminus-5_1-swings-to-q4-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3252347-wireless-telecomminus-5_1-swings-to-q4-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252335\" data-ts=\"1490045958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252335-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology'>IGT</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/ALR' title='Alere Inc.'>ALR</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+1.7%</font>. <a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+1.6%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='red'>-3.5%</font>. <a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a> <font color='red'>-3.1%</font>. <a href='https://seekingalpha.com/symbol/GEL' title='Genesis Energy, L.P.'>GEL</a> <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/FSM' title='Fortuna Silver Mines'>FSM</a> <font color='red'>-1.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252335\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$KEM $IGT $ALR - After Hours Gainers / Losers https://seekingalpha.com/news/3252335-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252335-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252332\" data-ts=\"1490045132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSM\" target=\"_blank\">FSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252332-fortuna-silver-warns-of-possible-delay-in-filing-2015-2016-financials\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortuna Silver warns of possible delay in filing 2015, 2016 financials</a></h4><ul><li>Fortuna SIlver Mines (NYSE:<a href='https://seekingalpha.com/symbol/FSM' title='Fortuna Silver Mines'>FSM</a>) <font color='red'>-2.5%</font>&nbsp;AH after saying it <a href=\"https://seekingalpha.com/pr/16776101-fortuna-announces-possible-delay-filing-annual-financial-results\" target=\"_blank\">may be delayed in filing</a> its annual  audited financial statements for 2015 and 2016, citing an ongoing SEC review of its 2015 annual filings.</li><li>FSM says the SEC has provided comments on its use of inferred resources  in its audited financial statements for the calculation of depletion  expenses; FSM says it considers the use of inferred resources in the  calculation of depletion expenses to be appropriate under IFRS and  consistent with the practice of other Canadian mining companies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252332\" data-linked=\"Fortuna Silver warns of possible delay in filing 2015, 2016 financials\" data-tweet=\"$FSM - Fortuna Silver warns of possible delay in filing 2015, 2016 financials https://seekingalpha.com/news/3252332-fortuna-silver-warns-of-possible-delay-in-filing-2015-2016-financials?source=tweet\" data-url=\"https://seekingalpha.com/news/3252332-fortuna-silver-warns-of-possible-delay-in-filing-2015-2016-financials\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252321\" data-ts=\"1490043101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252321-ocular-finance-chief-bids-adieu-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular finance chief bids adieu; shares down 3% after hours</a></h4><ul><li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>) eases&nbsp;<font color='red'>3%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/filing/3467991\" target=\"_blank\">announcement </a>that CFO W. Bradford Smith will resign at the end of the month to pursue other opportunities. He has agreed to consult through the end of May to assist with the transition to his successor.</li><li>COO James Fortune will assume the role of principal financial officer and principal accounting officer on an interim basis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252321\" data-linked=\"Ocular finance chief bids adieu; shares down 3% after hours\" data-tweet=\"$OCUL - Ocular finance chief bids adieu; shares down 3% after hours https://seekingalpha.com/news/3252321-ocular-finance-chief-bids-adieu-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252321-ocular-finance-chief-bids-adieu-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252305\" data-ts=\"1490041310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMSI\" target=\"_blank\">MMSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252305-merit-medical-readies-125m-equity-offering-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merit Medical readies $125M equity offering; shares up 2% after hours</a></h4><ul><li>Merit Medical Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/MMSI' title='Merit Medical Systems, Inc.'>MMSI</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/16776068-merit-medical-announces-commencement-public-offering-common-stock\" target=\"_blank\">initiates </a>a $125M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252305\" data-linked=\"Merit Medical readies $125M equity offering; shares up 2% after hours\" data-tweet=\"$MMSI - Merit Medical readies $125M equity offering; shares up 2% after hours https://seekingalpha.com/news/3252305-merit-medical-readies-125m-equity-offering-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252305-merit-medical-readies-125m-equity-offering-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252298\" data-ts=\"1490040999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252298-la-jolla-pharmaceutical-readies-100m-equity-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La Jolla Pharmaceutical readies $100M equity offering; shares down 4% after hours</a></h4><ul><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) is down&nbsp;<font color='red'>4%</font>&nbsp;after hours on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16776065-la-jolla-pharmaceutical-company-announces-proposed-underwritten-public-offering-common-stock\" target=\"_blank\">announcement </a>of a $100M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Net proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252298\" data-linked=\"La Jolla Pharmaceutical readies $100M equity offering; shares down 4% after hours\" data-tweet=\"$LJPC - La Jolla Pharmaceutical readies $100M equity offering; shares down 4% after hours https://seekingalpha.com/news/3252298-la-jolla-pharmaceutical-readies-100m-equity-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252298-la-jolla-pharmaceutical-readies-100m-equity-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252299\" data-ts=\"1490040940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEL\" target=\"_blank\">GEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252299-genesis-energy-to-launch-4m-unit-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genesis Energy to launch 4M-unit offering</a></h4><ul>     <li>Genesis Energy (NYSE:<a href='https://seekingalpha.com/symbol/GEL' title='Genesis Energy, L.P.'>GEL</a>) <font color='red'>-1.9%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16776093-genesis-energy-l-p-announces-public-offering-common-units\" target=\"_blank\">public offering</a> of 4M common units, with an underwriters option to purchase up to an additional 600K units.</li>     <li>GEL says it plans to use the proceeds for general partnership purposes, including funding acquisitions       or repaying part of the borrowings outstanding under its revolving credit facility.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252299\" data-linked=\"Genesis Energy to launch 4M-unit offering\" data-tweet=\"$GEL - Genesis Energy to launch 4M-unit offering https://seekingalpha.com/news/3252299-genesis-energy-to-launch-4m-unit-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3252299-genesis-energy-to-launch-4m-unit-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252292\" data-ts=\"1490040740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUPH\" target=\"_blank\">AUPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252292-aurinia-closes-173m-equity-offering-shares-ahead-16-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurinia closes $173M equity offering; shares ahead 16% after hours</a></h4><ul><li>Aurinia Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a>) has <a href=\"https://seekingalpha.com/pr/16776072-aurinia-closes-us-173_1-million-public-offering-common-shares-full-exercise-underwriters\" target=\"_blank\">closed </a>its previously announced public offering of common stock. Including the over-allotment to underwriters, the company sold 25.645M shares at $6.75 generating gross proceeds of $173.1M.</li><li>Shares are up&nbsp;<font color='green'>16%</font>&nbsp;after hours on average volume.</li><li><strong>Update</strong>: Shares are now up 1% after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252292\" data-linked=\"Aurinia closes $173M equity offering; shares ahead 16% after hours\" data-tweet=\"$AUPH - Aurinia closes $173M equity offering; shares ahead 16% after hours https://seekingalpha.com/news/3252292-aurinia-closes-173m-equity-offering-shares-ahead-16-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252292-aurinia-closes-173m-equity-offering-shares-ahead-16-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252289\" data-ts=\"1490040407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALA\" target=\"_blank\">CALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252289-calithera-launches-4_5m-share-stock-offering-shares-ease-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calithera launches 4.5M-share stock offering; shares ease 7% after hours</a></h4><ul><li>Calithera Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a>) <a href=\"https://seekingalpha.com/pr/16776069-calithera-biosciences-inc-announces-commencement-underwritten-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of 4.5M shares of common stock. Underwriters over-allotment will be an additional 675K shares. Price and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>7%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252289\" data-linked=\"Calithera launches 4.5M-share stock offering; shares ease 7% after hours\" data-tweet=\"$CALA - Calithera launches 4.5M-share stock offering; shares ease 7% after hours https://seekingalpha.com/news/3252289-calithera-launches-4_5m-share-stock-offering-shares-ease-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252289-calithera-launches-4_5m-share-stock-offering-shares-ease-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252280\" data-ts=\"1490039736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252280-analysts-say-medicines-companys-cholesterol-fighter-inclisiran-winner-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts say Medicines Company&#39;s cholesterol fighter inclisiran a winner; shares ahead 6%</a></h4><ul><li>The Medicines Company (<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='green'>+6.2%</font>) perks up on 50% higher volume on the heels of bullish comments from analysts about cholesterol-lowering inclisiran. The stock is clawing back from a&nbsp;<font color='red'>26%</font>&nbsp;plunge on Friday after the company <a href=\"https://seekingalpha.com/pr/16774602-medicines-company-alnylam-pharmaceuticals-report-positive-final-results-orionminus-1-phase-ii\" target=\"_blank\">announced </a>data from a Phase 2 study called ORION-1, weighed down by selling in Amgen after it announced CVOT data on Repatha (evolocumab).</li><li>H.C. Wainwright's Ed Arce: Orion-1 data \"robust\", inclisiran will be favored over Repatha considering its more convenient twice-yearly dosing regimen and lower cost (less than $5K). Rating: Buy/$60.</li><li>Evercore's Umer Raffat: Big plus is the ability to file an NDA before cardiovascular outcomes study completed. Rating: Outperform/$52.</li><li>Jefferies' Biren Amin: Safety profile \"continues to be clean.\" Co. pursuing strategic options but is not waiting for a transaction before starting Phase 3 study. Rating: Buy/$62.</li><li>Source: Bloomberg</li><li>Inclisiran (PCSK9si)&nbsp;is an investigational GalNAc-conjugated RNAi therapeutic targeting PCSK9, a protein regulator of LDL receptor metabolism. In contrast to PCSK9 inhibitors (like Repatha), PCSK9si works by turning off PCSK9 synthesis in the liver.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252280\" data-linked=\"Analysts say Medicines Company&#39;s cholesterol fighter inclisiran a winner; shares ahead 6%\" data-tweet=\"$MDCO - Analysts say Medicines Company&#39;s cholesterol fighter inclisiran a winner; shares ahead 6% https://seekingalpha.com/news/3252280-analysts-say-medicines-companys-cholesterol-fighter-inclisiran-winner-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3252280-analysts-say-medicines-companys-cholesterol-fighter-inclisiran-winner-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252281\" data-ts=\"1490039316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252281-instinet-reiterates-micron-technology-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Instinet reiterates Micron Technology at Buy</a></h4><ul><li>Considering DRAM spot pricing a point of over-emphasis among Micron Technology investors and the present setup of shares notably unalike peaks in 2014 (from where shares are currently trading&nbsp;<font color='red'>lower by&nbsp;28%</font>), <a href=\"http://blogs.barrons.com/techtraderdaily/2017/03/20/microns-depressed-stock-reflects-too-much-pessimism-says-instinet/\" target=\"_blank\">analyst Romit Shah</a> calculates operating margin estimates of 26% for the May term, indicating according to firm's model (regression 0.82), trade at $32 (2.7x book multiple). Projects May-period EPS guide of $1, a level not similarly recorded since November 2014 ($0.96) when shares were trading in the mid-$30s.</li><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) $26.21,&nbsp;<font color='green'>+1.59%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252281\" data-linked=\"Instinet reiterates Micron Technology at Buy\" data-tweet=\"$MU - Instinet reiterates Micron Technology at Buy https://seekingalpha.com/news/3252281-instinet-reiterates-micron-technology-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3252281-instinet-reiterates-micron-technology-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252278\" data-ts=\"1490038504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252278-israel-comms-ministry-approves-cellcom-xfone-sharing-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Israel comms ministry approves Cellcom/Xfone sharing deal</a></h4><ul>   <li>Cellcom Israel (<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel, Ltd.'>CEL</a> <font color='green'>+1.9%</font>) has <a href=\"https://seekingalpha.com/pr/16775065-cellcom-israel-announces-moc-approval-network-sharing-hosting-agreement-xfone\" target=\"_blank\">gotten approval</a> from Israel's Ministry of Communications for a network sharing and hosting services arrangement it's made with Marathon 018 Xfone.</li>    <li>That follows a <a href=\"https://seekingalpha.com/news/3218662-cellcom-plus-2_5-percent-getting-antitrust-ok-xfone-sharing-deal\" target=\"_blank\">previous approval</a> from the Antitrust Commissioner.</li>    <li>Shares are <font color='green'>up 1.9%</font> today and hit a 52-week high in U.S. trading on March 1; since the antitrust approval, they're <font color='green'>up 45%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252278\" data-linked=\"Israel comms ministry approves Cellcom/Xfone sharing deal\" data-tweet=\"$CEL - Israel comms ministry approves Cellcom/Xfone sharing deal https://seekingalpha.com/news/3252278-israel-comms-ministry-approves-cellcom-xfone-sharing-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3252278-israel-comms-ministry-approves-cellcom-xfone-sharing-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252275\" data-ts=\"1490036522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252275-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/TZOO' title='Travelzoo Inc'>TZOO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/IDSY' title='I.D. Systems, Inc.'>IDSY</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LUNA' title='Luna Innovations Incorporated'>LUNA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SEV' title='Sevcon, Inc.'>SEV</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252275\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$MVIS $YGE $TZOO - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3252275-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252275-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252273\" data-ts=\"1490036379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252273-grubhub-stirs-debate-over-fate-in-young-online-ordering-space\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub stirs debate over fate in young online ordering space</a></h4><ul>   <li>GrubHub (<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a> <font color='green'>+1.4%</font>) has been in for volatile trading today -- <font color='red'>down as much as 2.2%</font> before recovering -- amid a  <a href=\"http://www.barrons.com/articles/why-barrons-says-grubhubs-in-trouble-1490028934\" target=\"_blank\">bearish take</a> from <i>Barron's</i> (but some positivity from Raymond James).</li>    <li>The company has strong market share in the online-ordering space now, but that can change in a flash, <i>Barron's</i> argues -- particularly with ramp-ups from rivals with better delivery capability, including Amazon.com (which can offer free delivery to Prime members) and Uber.</li>    <li>GrubHub's also already moved into areas with lower-hanging fruit from an infrastructure perspective: New York and Chicago account for 70-75% of the company's orders.&nbsp;It could have a tougher time in areas where residents aren't so used to takeout eating.</li>    <li>Meanwhile, that leading share will serve it well in a market still in its infancy, says Raymond James' Aaron Kessler. Online ordering still accounts for just 10% of takeout orders, he argues, and GrubHub could ride that to a $46 share price (32% upside).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252273\" data-linked=\"GrubHub stirs debate over fate in young online ordering space\" data-tweet=\"$GRUB - GrubHub stirs debate over fate in young online ordering space https://seekingalpha.com/news/3252273-grubhub-stirs-debate-over-fate-in-young-online-ordering-space?source=tweet\" data-url=\"https://seekingalpha.com/news/3252273-grubhub-stirs-debate-over-fate-in-young-online-ordering-space\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252269\" data-ts=\"1490035112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGC\" target=\"_blank\">EGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252269-energy-xxi-hires-morgan-stanley-for-strategic-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy XXI hires Morgan Stanley for strategic plan</a></h4><ul>     <li>Energy XXI (EXXI <font color='green'>+5.4%</font>) is higher after saying it has hired investment bankers at Morgan Stanley to assist with <a href=\"http://ir.energyxxi.com/releasedetail.cfm?ReleaseID=1017950&amp;CompanyID=EXXI\" target=\"_blank\">developing a strategic plan</a>, including a stand-alone financial plan and selected strategic alternatives.</li>     <li>EXXI's move to retain financial advisors follows the completion a financial restructuring process and re-listing its stock on Nasdaq.</li><li>EXXI also says it continues to search for a permanent CEO following last month's appointment of Michael Reddin as interim CEO after John Schiller stepped down as CEO and President, and promoting chief accounting officer Hugh Menown to CFO after Bruce Busmire announced plans to pursue other interests.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252269\" data-linked=\"Energy XXI hires Morgan Stanley for strategic plan\" data-tweet=\"$EGC - Energy XXI hires Morgan Stanley for strategic plan https://seekingalpha.com/news/3252269-energy-xxi-hires-morgan-stanley-for-strategic-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3252269-energy-xxi-hires-morgan-stanley-for-strategic-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252265\" data-ts=\"1490032841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252265-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling SA'>PACD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NTIC' title='Northern Technologies International Corporation'>NTIC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/TGA' title='Transglobe Energy Corp'>TGA</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252265\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$DDC $MCF $NAK - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3252265-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252265-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252262\" data-ts=\"1490032334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252262-financials-continue-to-struggle-post-rate-hike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials continue to struggle post-rate hike</a></h4><ul><li>The major averages are off just a fraction today, but the <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> and <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> are&nbsp;<font color='red'>down 1%</font>, and the broader financial sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>),<font color='red'> 0.5%</font>.</li><li>In a bit of buy the rumor/sell the news action, interest rates - and with them financials/banks - topped out just ahead of the Fed rate hike last Wednesday.</li><li>The 10-year Treasury yield - above 2.60% ahead of the Fed move - is down another three basis points today to 2.47%.</li><li>BofA (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-1.3%</font>), Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-1.1%</font>), Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-0.8%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-0.4%</font>), BB&amp;T (<a href='https://seekingalpha.com/symbol/BBT' title='BB&T Corporation'>BBT</a> <font color='red'>-0.6%</font>), U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-0.1%</font>), MetLife (<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='red'>-0.2%</font>), Prudential (<a href='https://seekingalpha.com/symbol/PRU' title='Prudential Financial, Inc.'>PRU</a> <font color='red'>-0.4%</font>), Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='red'>-0.9%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252262\" data-linked=\"Financials continue to struggle post-rate hike\" data-tweet=\"$BAC $KRE $KBE - Financials continue to struggle post-rate hike https://seekingalpha.com/news/3252262-financials-continue-to-struggle-post-rate-hike?source=tweet\" data-url=\"https://seekingalpha.com/news/3252262-financials-continue-to-struggle-post-rate-hike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252254\" data-ts=\"1490030172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252254-meetme-initiated-outperform-canaccord-genuity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MeetMe initiated at Outperform at Canaccord Genuity</a></h4><ul><li>Setting $10 target, <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9190952/analyst-introduces-buy-rating-on-meetme-sees-almost-50-u\" target=\"_blank\">analyst Michael Graham</a> highlights incremental growth potential through international monetization, acquisition-based revenue synergies and video live-streaming initiatives.</li><li>MeetMe (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) $5.45,&nbsp;<font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252254\" data-linked=\"MeetMe initiated at Outperform at Canaccord Genuity\" data-tweet=\"$MEET - MeetMe initiated at Outperform at Canaccord Genuity https://seekingalpha.com/news/3252254-meetme-initiated-outperform-canaccord-genuity?source=tweet\" data-url=\"https://seekingalpha.com/news/3252254-meetme-initiated-outperform-canaccord-genuity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252256\" data-ts=\"1490030118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252256-financials-top-5-gainers-losers-of-1-15-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:15 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MTR' title='Mesa Royalty Trust'>MTR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CIA' title='Citizens, Inc.'>CIA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FRBA' title='First Bank &#40;Nj&#41;'>FRBA</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252256\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:15 PM\" data-tweet=\"$HAWK $JP $MTR - Financials - Top 5 Gainers / Losers as of 1:15 PM https://seekingalpha.com/news/3252256-financials-top-5-gainers-losers-of-1-15-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252256-financials-top-5-gainers-losers-of-1-15-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252251\" data-ts=\"1490029119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252251-transoceanminus-2-despite-rig-sale-analyst-says-earlier-report-misinterpreted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean -2% despite rig sale; analyst says earlier report &quot;misinterpreted&quot;</a></h4><ul><li>Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-2.2%</font>) is lower despite the news that Borr Drilling will <a href=\"https://seekingalpha.com/news/3252173-transocean-sell-entire-jack-fleet-1_35b-deal\" target=\"_blank\">acquire</a> its entire fleet of 15 jack-up drilling rigs in a deal valued at $1.35B.</li><li>Reports surfaced <a href=\"https://seekingalpha.com/news/3250712-transocean-extends-gains-may-near-1_2b-deal-sell-15-rigs\" target=\"_blank\">last week</a> that the rigs could be acquired for $1.2B, and BMO Capital analyst Dan Boyd believes \"some analysts <a href=\"http://www.cnbc.com/2017/03/20/transocean-rig-sale-to-borr-drilling.html\" target=\"_blank\">grossly misinterpreted</a> the news last week and did not  account for the remaining new-build liability payments of more than $1.1B.\"</li><li>RIG still owes $1.1B in newbuild payments on its rigs,  according to BMO, and Boyd doubts Borr's acquisition price of  the rigs includes the lingering liabilities, \"as that would imply Borr  paying full replacement cost.\"</li><li>Evercore ISI's James&nbsp;West is much more upbeat, reiterating that it would be \"<a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/20/transocean-be-aggressive-2/\" target=\"_blank\">aggressive buyers</a>\" of RIG the deal monetizes RIG&rsquo;s under-utilized jack-up fleet and significantly reduces debt and capex.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252251\" data-linked=\"Transocean -2% despite rig sale; analyst says earlier report &quot;misinterpreted&quot;\" data-tweet=\"$RIG - Transocean -2% despite rig sale; analyst says earlier report &quot;misinterpreted&quot; https://seekingalpha.com/news/3252251-transoceanminus-2-despite-rig-sale-analyst-says-earlier-report-misinterpreted?source=tweet\" data-url=\"https://seekingalpha.com/news/3252251-transoceanminus-2-despite-rig-sale-analyst-says-earlier-report-misinterpreted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252247\" data-ts=\"1490028439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252247-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics'>BLPH</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> CERU <font color='red'>-63%</font>. <a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-57%</font>. <a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='red'>-30%</font>. ARGS <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corp.'>TWMC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252247\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ESPR $BLPH $NKTR - Midday Gainers / Losers https://seekingalpha.com/news/3252247-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252247-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252244\" data-ts=\"1490027896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTTR\" target=\"_blank\">RTTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252244-zacks-bearish-on-ritter-pharma-shares-slump-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zacks bearish on Ritter Pharma; shares slump 17%</a></h4><ul><li>Thinly traded nano cap Ritter Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-17.1%</font>) is down on triple normal volume on the heels of a <a href=\"http://petroglobalnews24.com/2017-03-20-ritter-pharmaceuticals-inc-rttr-downgraded-to-sell-at-zacks-investment-research/\" target=\"_blank\">downgrade </a>to Sell by Zacks Investment Research.</li><li>Perennial bulls Aegis, Roth Capital and Maxim Group have Buy ratings on the stock with price targets of $9 (420% upside), $6 (228% upside) and $5 (173% upside), respectively. Chardan Capital also <a href=\"http://petroglobalnews24.com/2017-03-15-ritter-pharmaceuticals-inc-rttr-rating-reiterated-by-aegis/\" target=\"_blank\">rates it a Buy</a> with a fair value target of $5.</li><li>Data from a Phase 2b/3 clinical trial assessing lead product candidate RP-G28 for the treatment of lactose intolerance are expected any time.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3214676-monitoring-visits-completed-ritters-late-stage-study-lead-product-candidate-rp-g28-top-line\" target=\"_blank\">Monitoring visits completed in Ritter's late-stage study of lead product candidate RP-G28, top-line data expected in Q1; shares up 24%</a> (Oct. 18, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252244\" data-linked=\"Zacks bearish on Ritter Pharma; shares slump 17%\" data-tweet=\"$RTTR - Zacks bearish on Ritter Pharma; shares slump 17% https://seekingalpha.com/news/3252244-zacks-bearish-on-ritter-pharma-shares-slump-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3252244-zacks-bearish-on-ritter-pharma-shares-slump-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252238\" data-ts=\"1490025700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252238-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/FBR' title='Fibria Celulose S.A.'>FBR</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252238\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ABAC-OLD $SPWH $FBR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3252238-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252238-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252240\" data-ts=\"1490025514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPLA\" target=\"_blank\">LPLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252240-lpl-financial-upgraded-to-buy-goldman-negatives-become-positives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LPL Financial upgraded to Buy at Goldman as negatives become positives</a></h4><ul>     <li>LPL Financial Holdings (<a href='https://seekingalpha.com/symbol/LPLA' title='LPL Financial Holdings Inc.'>LPLA</a> <font color='green'>+1.8%</font>)&nbsp;is higher after Goldman Sachs <a href=\"http://blogs.barrons.com/focusonfunds/2017/03/20/goldman-sachs-time-to-buy-lpl-financial-holdings/?mod=BOL_hp_blog_fof\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $47 price target, saying the headwinds LPLA faced last year - debt covenant constraints, low interest rates, and asset-based fee pressure - have become tailwinds.</li>     <li>&ldquo;Additionally, while the company trades relatively in line with peers, given debt covenant issues have now passed and we expect buybacks to resume, we believe investors will again ascribe value to LPLA&rsquo;s less capital intensive model,\" the firm writes.</li>     <li>Using the low end of LPLA&rsquo;s 3.25x-3.5x leverage target, Goldman sees the company as having $555M of &ldquo;excess cash&rdquo; by year-end 2017; the firm does not expect all the cash to be deployed, but believes it underscores improving capital flexibility and provides upside to its 2017 buyback estimate of $120M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252240\" data-linked=\"LPL Financial upgraded to Buy at Goldman as negatives become positives\" data-tweet=\"$LPLA - LPL Financial upgraded to Buy at Goldman as negatives become positives https://seekingalpha.com/news/3252240-lpl-financial-upgraded-to-buy-goldman-negatives-become-positives?source=tweet\" data-url=\"https://seekingalpha.com/news/3252240-lpl-financial-upgraded-to-buy-goldman-negatives-become-positives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252235\" data-ts=\"1490025159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252235-loxo-oncology-teams-up-ventana-medical-on-companion-diagnostic-for-larotrectinib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loxo Oncology teams up with Ventana Medical on companion diagnostic for larotrectinib</a></h4><ul><li>Loxo Oncology (<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+1.9%</font>) inks a <a href=\"https://seekingalpha.com/pr/16775091-loxo-oncology-announces-larotrectinib-pan-trk-ihc-companion-diagnostic-collaboration-ventana\" target=\"_blank\">collaboration agreement</a> with Roche's Ventana Medical Systems aimed at developing and commercializing a pan-TRK immunohistochemistry &#40;IHC&#41; test as a companion diagnostic to identify suitable patients for treatment with Loxo's lead product candidate larotrectinib (LOXO-101).</li><li>The companies will work with an investigational assay piloted by Loxo that will be further developed by Roche using its OptiView DAB detection technology. Roche will be responsible for obtaining regulatory approvals in the U.S. and countries that recognize the CE Mark. Financial terms are not disclosed.</li><li><a href=\"https://www.loxooncology.com/pipeline#loxo-101\" target=\"_blank\">LOXO-101</a>&nbsp;inhibits a group of enzymes called tropomyosin receptor kinases &#40;TRK&#41;, a group of proteins that play a key role in cellular communications. Cancers hijack these communication pathways to send messages to the cells to grow, change or survive. Those characterized by these alterations, termed NTRK fusions, are the therapeutic targets for LOXO-101.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252235\" data-linked=\"Loxo Oncology teams up with Ventana Medical on companion diagnostic for larotrectinib\" data-tweet=\"$LOXO - Loxo Oncology teams up with Ventana Medical on companion diagnostic for larotrectinib https://seekingalpha.com/news/3252235-loxo-oncology-teams-up-ventana-medical-on-companion-diagnostic-for-larotrectinib?source=tweet\" data-url=\"https://seekingalpha.com/news/3252235-loxo-oncology-teams-up-ventana-medical-on-companion-diagnostic-for-larotrectinib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252234\" data-ts=\"1490024804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFM\" target=\"_blank\">SFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252234-sprouts-bidding-war-may-ensue-jefferies-says-maintains-buy-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprouts bidding war may ensue, Jefferies says as it maintains Buy rating</a></h4><ul>     <li>Sprouts Farmers Market (<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='red'>-1.5%</font>) turns lower even after reports that privately-held Albertson&rsquo;s could be <a href=\"https://seekingalpha.com/news/3252113-albertsons-considers-merger-sprouts\" target=\"_blank\">interested in acquiring it</a>, as investors that were active in SFM ahead of the news now <a href=\"https://www.benzinga.com/news/17/03/9191626/sprouts-farmers-market-six-day-winning-streak-in-jeopardy\" target=\"_blank\">take profits</a>.</li>     <li><a href=\"http://thefly.com/landingPageNews.php?id=2522470&amp;headline=SFM;WFM;KR;NGVC-After-Albertsons-report-analyst-says-Sprouts-bidding-war-may-ensue\" target=\"_blank\">Maintaining its Buy rating</a> and $22 stock price target, Jefferies analysts call SFM \"one of the few high quality growth platforms remaining in grocery\" and  predict that it will continue to gain market share, The Fly.com reports.</li><li>Based on historical transactions in the grocery space and its belief that sales trends \"remain good,\" Jefferies estimates SFM could be acquired for $26.</li>     <li>Meanwhile, larger rival Whole Foods Market (WFM <font color='green'>+0.9%</font>) is higher in a related trade.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252234\" data-linked=\"Sprouts bidding war may ensue, Jefferies says as it maintains Buy rating\" data-tweet=\"$SFM $SFM $AMZN - Sprouts bidding war may ensue, Jefferies says as it maintains Buy rating https://seekingalpha.com/news/3252234-sprouts-bidding-war-may-ensue-jefferies-says-maintains-buy-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3252234-sprouts-bidding-war-may-ensue-jefferies-says-maintains-buy-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252232\" data-ts=\"1490023959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252232-biolinerxs-lead-product-candidate-shows-encouraging-advantages-over-g-csf-in-stem-cell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx&#39;s lead product candidate shows encouraging advantages over G-CSF in stem cell mobilization</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16775118-biolinerx-provides-update-phase-2-open-label-study-blminus-8040-novel-stem-cell-mobilization\" target=\"_blank\">Preliminary results</a> from a small open-label Phase 2 study of BioLineRx's (<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color='red'>-4.2%</font>) lead product candidate BL-8040 showed that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a similar level of efficacy to 4 - 6 injections of granulocyte colony-stimulating factor (G-CSF), the current standard of care. All recipients have experienced successful neutrophil (type of white blood cell) engraftment.</li><li>Part 1 of the study involves 10 donor/recipient pairs consisting of 10 patients with advanced blood cancers and their HLA-matched sibling donors. If no safety signals are observed regarding graft failure or rejection, the study will advance to Part 2 which will enroll 24 donor/recipient pairs, either matched siblings or haploidentical (HLA-matched) donors. Top-line data are expected by year-end.</li><li>The value proposition of BL-8040 compared to G-CSF is more rapid mobilization of hematopoietic stem cells in a more patient-friendly way. BL-8040 is dosed once with up to a two-day collection regimen versus four-to-six daily injections of G-CSF and one-to-four apheresis sessions.</li><li><a href=\"http://www.biolinerx.com/default.asp?pageid=98&amp;itemid=41\" target=\"_blank\">BL-8040</a> is a short peptide for the treatment of acute myeloid leukemia, solid tumors and certain hematological indications. It functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity.</li><li>Shares were up almost<font color='green'> 8%</font>&nbsp;before retracing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252232\" data-linked=\"BioLineRx&#39;s lead product candidate shows encouraging advantages over G-CSF in stem cell mobilization\" data-tweet=\"$BLRX - BioLineRx&#39;s lead product candidate shows encouraging advantages over G-CSF in stem cell mobilization https://seekingalpha.com/news/3252232-biolinerxs-lead-product-candidate-shows-encouraging-advantages-over-g-csf-in-stem-cell?source=tweet\" data-url=\"https://seekingalpha.com/news/3252232-biolinerxs-lead-product-candidate-shows-encouraging-advantages-over-g-csf-in-stem-cell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252231\" data-ts=\"1490023494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAWK\" target=\"_blank\">HAWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252231-blackhawk-adds-two-new-directors-in-deal-jana-partners\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blackhawk adds two new directors in deal with Jana Partners</a></h4><ul>     <li>Blackhawk Network Holdings (<a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a> <font color='green'>+7.2%</font>) surges near 52-week highs after saying it will <a href=\"https://seekingalpha.com/pr/16775046-blackhawk-network-holdings-inc-jana-partners-announce-addition-two-new-independent-directors\" target=\"_blank\">add two new independent directors</a> following an agreement with activist investor Jana Partners, which owns a ~4.7% stake in the company.</li><li>Under the agreement with Jana, HAWK also will form a committee that will evaluate all options for increasing  cost savings.</li><li>Also, CFO Jerry Ulrich says he plans to retire by the end of this year, and the company has initiated a search to identify a replacement; he has been HAWK's CEO since joining the company in 2006.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252231\" data-linked=\"Blackhawk adds two new directors in deal with Jana Partners\" data-tweet=\"$HAWK - Blackhawk adds two new directors in deal with Jana Partners https://seekingalpha.com/news/3252231-blackhawk-adds-two-new-directors-in-deal-jana-partners?source=tweet\" data-url=\"https://seekingalpha.com/news/3252231-blackhawk-adds-two-new-directors-in-deal-jana-partners\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252224\" data-ts=\"1490022131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252224-healthcare-top-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics'>BLPH</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> CERU <font color='red'>-61%</font>. <a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-55%</font>. ARGS <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252224\" data-linked=\"Healthcare - Top Gainers / Losers as of 11:00 am\" data-tweet=\"$ESPR $BLPH $NKTR - Healthcare - Top Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3252224-healthcare-top-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3252224-healthcare-top-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252219\" data-ts=\"1490021280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252219-sonic-downgraded-to-hold-from-buy-canaccord-amid-increased-competition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonic downgraded to Hold from Buy at Canaccord amid increased competition</a></h4><ul><li>Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='red'>-2.6%</font>) is lower after Canaccord Genuity <a href=\"http://www.marketwatch.com/story/sonic-downgraded-on-increased-competition-from-convenience-stores-2017-03-20\" target=\"_blank\">downgrades</a> shares to Hold from Buy and cuts its price target to $24 from $30, citing soft sales in recent months and growing food and drink competition from retail channels such as convenience stores.</li><li>Canaccord believes industry sales will continue to be challenging, and intense  promoting and discounting will remain a theme, as quick service restaurant  companies fight for market share, and sees no identifiable catalysts for material same-store sales improvement in the coming months.</li><li>SONC shares already are 27% lower over the past year vs. a 16% gain for the S&amp;P 500.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252219\" data-linked=\"Sonic downgraded to Hold from Buy at Canaccord amid increased competition\" data-tweet=\"$SONC - Sonic downgraded to Hold from Buy at Canaccord amid increased competition https://seekingalpha.com/news/3252219-sonic-downgraded-to-hold-from-buy-canaccord-amid-increased-competition?source=tweet\" data-url=\"https://seekingalpha.com/news/3252219-sonic-downgraded-to-hold-from-buy-canaccord-amid-increased-competition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252218\" data-ts=\"1490021237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MESO\" target=\"_blank\">MESO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252218-mesoblasts-cell-therapy-shows-durable-treatment-effect-in-mid-stage-study-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mesoblast&#39;s cell therapy shows durable treatment effect in mid-stage study; shares ahead 4%</a></h4><ul><li>Ultra-thinly traded micro cap Mesoblast (<a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast'>MESO</a> <font color='green'>+3.7%</font>) perks up on average volume in response to its <a href=\"https://seekingalpha.com/pr/16771436-durable-three-year-outcomes-degenerative-disc-disease-single-injection-mesoblast-s-cell\" target=\"_blank\">announcement </a>of positive long-term results from a 100-subject Phase 2 study assessing its proprietary allogeneic Mesenchymal Precursor Cells (MPCs) in patients with chronic low back pain due to disc degeneration.</li><li>The data showed a single intra-discal injection of 6M MPCs produced meaningful improvements in pain and function that persisted for at least 36 months.</li><li>The 36-month data support the ongoing 360-patient Phase 3 study of MPC-06-ID by reinforcing the rationale of MPC dose selection.</li><li>The company is in negotiations with Mallinckrodt for commercialization rights.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252218\" data-linked=\"Mesoblast&#39;s cell therapy shows durable treatment effect in mid-stage study; shares ahead 4%\" data-tweet=\"$MESO - Mesoblast&#39;s cell therapy shows durable treatment effect in mid-stage study; shares ahead 4% https://seekingalpha.com/news/3252218-mesoblasts-cell-therapy-shows-durable-treatment-effect-in-mid-stage-study-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3252218-mesoblasts-cell-therapy-shows-durable-treatment-effect-in-mid-stage-study-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252216\" data-ts=\"1490020459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252216-advanced-micro-devices-raised-to-16-target-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advanced Micro Devices raised to $16 target at Jefferies</a></h4><ul><li>From $13 (current price $14.22) and reiterating shares at Buy, <a href=\"http://www.streetinsider.com/Analyst+Comments/AMD+%28AMD%29+PT%2C+Estimates+Raised+to+%2416+at+Jefferies%3B+Ryzen+Launch+Underway/12684723.html\" target=\"_blank\">analyst Mark Lipacis</a> elevates sales estimates, citing greater visibility into Ryzen 7 and forthcoming Ryzen 5 launch (<a href=\"http://www.amd.com/en-us/press-releases/Pages/amd-ryzen-5-cpus-2017mar15.aspx\" target=\"_blank\">April 11</a>), and Advanced Micro Devices' (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+5.4%</font>) ability to balance pricing and competitive performance, which firm expects to result in material share gains at the expense of Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='green'>+0.8%</font>) within desktop, server and notebook segments beginning this year.</li><li>Models 2017 sales and EPS 700 bps and $0.17 over consensus forecasts, respectively.</li><li>Previously (March 13, 2017):&nbsp;<a href=\"https://seekingalpha.com/news/3250798-intel-downgraded-hold-jefferies\" target=\"_blank\">Intel downgraded to Hold at Jefferies</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252216\" data-linked=\"Advanced Micro Devices raised to $16 target at Jefferies\" data-tweet=\"$AMD $AMD $INTC - Advanced Micro Devices raised to $16 target at Jefferies https://seekingalpha.com/news/3252216-advanced-micro-devices-raised-to-16-target-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3252216-advanced-micro-devices-raised-to-16-target-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>133&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252211\" data-ts=\"1490019496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNMX\" target=\"_blank\">GNMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252211-aevi-genomics-lead-product-candidate-flunks-adhd-study-shares-plummet-56\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aevi Genomic&#39;s lead product candidate flunks ADHD study; shares plummet 56%</a></h4><ul><li>Thinly traded nano cap Aevi Genomic Medicine (<a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-56.4%</font>) craters on more than a 5x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16775097-aevi-genomic-medicine-provides-top-line-results-saga-trial-aeviminus-001\" target=\"_blank\">announcement </a>that lead product candidate <a href=\"http://www.aevigenomics.com/c/pipeline/index.php\" target=\"_blank\">AEVI-001</a> failed to beat placebo in its <a href=\"https://clinicaltrials.gov/ct2/show/NCT02777931?term=aevi+genomic+medicine&amp;rank=3\" target=\"_blank\">SAGA </a>clinical trial in adolescents with mGluR mutation-positive attention deficit hyperactivity disorder &#40;ADHD&#41;. The study did not achieve its primary endpoint of a statistically valid reduction in a rating scale called ADHD-RS.</li><li>The company remains hopeful, however, citing an encouraging improvement on the inattention subscale (p=0.0515) and data from a pre-specified analysis of high responders (ADHD-RS improvement of at least 30%) that showed a statistically significant greater proportion AEVI-001-treated patients in this group compared to placebo (70% vs. 42%; p=0.0067). The study also achieved a key secondary endpoint of a statistically valid effect as measured by another scale called CGI-I (57% vs. 33%; p=0.0155).</li><li>The company intends to discuss the data with the FDA and presenting the results at the World Congress on ADHD next month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252211\" data-linked=\"Aevi Genomic&#39;s lead product candidate flunks ADHD study; shares plummet 56%\" data-tweet=\"$GNMX - Aevi Genomic&#39;s lead product candidate flunks ADHD study; shares plummet 56% https://seekingalpha.com/news/3252211-aevi-genomics-lead-product-candidate-flunks-adhd-study-shares-plummet-56?source=tweet\" data-url=\"https://seekingalpha.com/news/3252211-aevi-genomics-lead-product-candidate-flunks-adhd-study-shares-plummet-56\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252207\" data-ts=\"1490018201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXTI\" target=\"_blank\">AXTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252207-needham-company-reiterates-axt-buy-production-fire-affected-facility-now-resumed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham &amp; Company reiterates AXT at Buy with production at fire-affected facility now resumed</a></h4><ul><li>Noting share pressure realized since last week on a <a href=\"https://seekingalpha.com/news/3251749-axt-minus-15_2-percent-fire-beijing-facility-impacts-manufacturing-production\" target=\"_blank\">production facility fire</a> and a <a href=\"https://seekingalpha.com/news/3251957-axt-minus-3-percent-pre-market-b-riley-and-co-downgrades-neutral\" target=\"_blank\">downgrade at B. Riley &amp; Co.</a> that compounded the resulting sell-off, AXT shares, at this point&nbsp;<font color='red'>lower by 22%+</font>&nbsp;since initial disclosure of the fire, are considered by <a href=\"http://www.streetinsider.com/Analyst+Comments/Apple+%28AAPL%29+PT+Raised+to+%24155+at+Cowen%2C+Street+Estimates+%22WAY+TOO+LOW%22/12684283.html\" target=\"_blank\">analyst Edwin Mok</a> largely reflective of downside and representative of an acquiring opportunity. Buy rating, $8.50 target reiterated.</li><li>AXT (NASDAQ:<a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a>) $5.74,&nbsp;<font color='green'>+3.51%</font>.</li><li>Earlier (March 20, 2017): <a href=\"https://seekingalpha.com/news/3252182-axt-plus-9_9-percent-recommences-substrate-production-beijing-facility\" target=\"_blank\">AXT +9.9%; recommences substrate production at Beijing facility</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252207\" data-linked=\"Needham &amp; Company reiterates AXT at Buy with production at fire-affected facility now resumed\" data-tweet=\"$AXTI - Needham &amp; Company reiterates AXT at Buy with production at fire-affected facility now resumed https://seekingalpha.com/news/3252207-needham-company-reiterates-axt-buy-production-fire-affected-facility-now-resumed?source=tweet\" data-url=\"https://seekingalpha.com/news/3252207-needham-company-reiterates-axt-buy-production-fire-affected-facility-now-resumed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252203\" data-ts=\"1490017839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAZZ\" target=\"_blank\">JAZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252203-jazz-pharmas-jzpminus-110-successful-in-two-late-stage-studies-in-obstructive-sleep-apnea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jazz Pharma&#39;s JZP-110 successful in two late-stage studies in obstructive sleep apnea; shares up 6%</a></h4><ul><li>Jazz Pharmaceuticals (<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals, Inc.'>JAZZ</a> <font color='green'>+6.1%</font>) perks up on increased volume in response to its announcement of <a href=\"https://seekingalpha.com/pr/16775501-jazz-pharmaceuticals-announces-positive-results-phase-3-tones-3-tones-4-studies-jzpminus-110\" target=\"_blank\">positive results</a> from two Phase 3 trials assessing Orphan Drug-tagged JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, for the treatment of excessive sleepiness in adults with obstructive sleep apnea &#40;OSA&#41;.</li><li>Both studies, TONES 3 and TONES 4, met their co-primary endpoints.</li><li>Results from TONES 2, assessing JZP-110 for the treatment of excessive sleepiness associated with narcolepsy, should be available next quarter. An NDA is on tap for Q4.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3210887-patient-enrollment-complete-jazz-pharmas-late-stage-studies-excessive-sleepiness-candidate\" target=\"_blank\">Patient enrollment complete in Jazz Pharma's late-stage studies of excessive sleepiness candidate JZP-110, top-line data expected in Q1 2017</a> (Sept. 26, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252203\" data-linked=\"Jazz Pharma&#39;s JZP-110 successful in two late-stage studies in obstructive sleep apnea; shares up 6%\" data-tweet=\"$JAZZ - Jazz Pharma&#39;s JZP-110 successful in two late-stage studies in obstructive sleep apnea; shares up 6% https://seekingalpha.com/news/3252203-jazz-pharmas-jzpminus-110-successful-in-two-late-stage-studies-in-obstructive-sleep-apnea?source=tweet\" data-url=\"https://seekingalpha.com/news/3252203-jazz-pharmas-jzpminus-110-successful-in-two-late-stage-studies-in-obstructive-sleep-apnea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252197\" data-ts=\"1490016540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARLZ-OLD\" target=\"_blank\">ARLZ-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252197-aralez-pharma-up-15-on-ceos-purchase-of-500k-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aralez Pharma up 15% on CEO&#39;s purchase of 500K shares</a></h4><ul><li>Aralez Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARLZ-OLD' title='Aralez Pharmaceuticals Inc.'>ARLZ-OLD</a>) perks up&nbsp;<font color='green'>15%</font>&nbsp;premarket on increased volume on the <a href=\"https://seekingalpha.com/pr/16775073-aralez-ceo-purchases-500000-shares-company-common-stock-open-market\" target=\"_blank\">news </a>that CEO Adrian Adams has purchased 500K shares on the open market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252197\" data-linked=\"Aralez Pharma up 15% on CEO&#39;s purchase of 500K shares\" data-tweet=\"$ARLZ-OLD - Aralez Pharma up 15% on CEO&#39;s purchase of 500K shares https://seekingalpha.com/news/3252197-aralez-pharma-up-15-on-ceos-purchase-of-500k-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3252197-aralez-pharma-up-15-on-ceos-purchase-of-500k-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252194\" data-ts=\"1490016189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESPR\" target=\"_blank\">ESPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252194-fda-on-board-esperions-late-stage-development-program-for-bad-cholesterol-lowering-claim-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA on board with Esperion&#39;s late-stage development program for bad cholesterol-lowering claim for bempedoic acid; shares ahead 33% premarket</a></h4><ul><li>Esperion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a>) is up&nbsp;<font color='green'>33%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16775162-esperion-announces-fda-confirmation-regarding-regulatory-pathway-approval-ldl-c-lowering\" target=\"_blank\">announcement</a> that the FDA has confirmed that the design of its Phase 3 program developing bempedoic acid for lowering low density lipoprotein cholesterol (LDL-C) is sufficient to support approval. Late-stage development began in January 2016 (Study 1). Three Phase 3 studies (Study 2, Study 3, Study 4) specific to LDL-C lowering are currently recruiting patients.</li><li>The company says that if all goes according to plan, it will be in position to submit a New Drug Application &#40;NDA&#41; by H1 2019.</li><li>A cardiovascular outcomes trial &#40;CVOT&#41; was initiated in Q4 2016 and will involve ~12,600 patients. An NDA for cardiovascular disease risk reduction could be filed by 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252194\" data-linked=\"FDA on board with Esperion&#39;s late-stage development program for bad cholesterol-lowering claim for bempedoic acid; shares ahead 33% premarket\" data-tweet=\"$ESPR - FDA on board with Esperion&#39;s late-stage development program for bad cholesterol-lowering claim for bempedoic acid; shares ahead 33% premarket https://seekingalpha.com/news/3252194-fda-on-board-esperions-late-stage-development-program-for-bad-cholesterol-lowering-claim-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3252194-fda-on-board-esperions-late-stage-development-program-for-bad-cholesterol-lowering-claim-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252193\" data-ts=\"1490015982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252193-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul> <li>CERU <font color='red'>-63%</font> on asset sale and Dar&eacute;&nbsp;Bioscience becoming major owner.<br></li><li><a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-60%</font> on ADHD-RS trial not meeting end-point.</li><li><a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-12%</font>.</li><li><a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='red'>-9%</font> on withdrawal of binimetinib application.<br></li><li><a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='red'>-8%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3252193\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$DARE $GNMX $PULM - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3252193-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3252193-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252191\" data-ts=\"1490015749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252191-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+30%</font> on expanded partnership with Bristol-Myers Squibb.</li><li><a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='green'>+28%</font> on FDA support approval of LDL-C lowering program.</li><li><a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+24%</font> on $1.1B takeover bid.</li><li><a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+20%</font> on positive results from Phase 3 trial of NKTR-18.</li><li><a href='https://seekingalpha.com/symbol/ARLZ-OLD' title='Aralez Pharmaceuticals Inc.'>ARLZ-OLD</a> <font color='green'>+16%</font> on CEO buying 500K shares.</li><li><a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics'>BLPH</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='green'>+10%</font> on patent allowance for RosettaGX Reveal Assay.</li><li><a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='green'>+7%</font> on preliminary takeover talks with Albertsons. </li><li><a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a> <font color='green'>+6%</font> on after BofA Merrill Lynch analyst upgrade.<br></li><li><a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3252191\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CTMX $ESPR $DDC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3252191-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3252191-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252183\" data-ts=\"1490015201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252183-cerulean-sells-assets-lays-off-staff-dar-bio-becomes-majority-owner-shares-plummet-62\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerulean sells assets, lays off staff as Dar Bio becomes majority owner; shares plummet 62% premarket</a></h4><ul><li>Nano cap Cerulean Pharma (CERU) craters&nbsp;<font color='red'>62%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16775193-cerulean-pharma-dare-bioscience-enter-stock-purchase-agreement\" target=\"_blank\">announcement</a> that it has sold certain assets for $7.5M in conjunction with a stock purchase deal with&nbsp;Dar&eacute;&nbsp;Bioscience making the La Jolla, CA-based firm the majority owner in Cerulean. The company will do business as&nbsp;Dar&eacute;&nbsp;Bioscience.</li><li>Cerulean has entered into an agreement with NewLink Genetics subsidiary BlueLink Pharmaceuticals for the sale of product candidates CRLX101 and CRLX301 for $1.5M and an agreement with Novartis for the sale of all rights to its Dynamic Tumor Targeting Platform for $6M, subject to CERU shareholder approval.</li><li>In connection with the transactions, Cerulean will pay off its debt facility with Hercules Capital and lay off 58% (11 employees) of its workforce.</li><li>The deals will enable Cerulean to transition its focus to women's reproductive health.&nbsp;Dar&eacute;'s lead product candidate is Ovaprene, a clinical-stage, non-hormonal contraceptive ring for monthly use, which it says is a significant unmet need.</li><li>Under the terms of the stock purchase agreement, Dar&eacute; stockholders will receive newly issued shares of Cerulean while outstanding Dar&eacute; options and convertible securities will be assumed by Cerulean. Depending on certain conditions, Cerulean stockholders will own 30 - 49% of the combined firm.</li><li>The boards of both companies have OK'd the deal, expected to close next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252183\" data-linked=\"Cerulean sells assets, lays off staff as Dar Bio becomes majority owner; shares plummet 62% premarket\" data-tweet=\"$DARE - Cerulean sells assets, lays off staff as Dar Bio becomes majority owner; shares plummet 62% premarket https://seekingalpha.com/news/3252183-cerulean-sells-assets-lays-off-staff-dar-bio-becomes-majority-owner-shares-plummet-62?source=tweet\" data-url=\"https://seekingalpha.com/news/3252183-cerulean-sells-assets-lays-off-staff-dar-bio-becomes-majority-owner-shares-plummet-62\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252182\" data-ts=\"1490014719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXTI\" target=\"_blank\">AXTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252182-axtplus-9_9-recommences-substrate-production-beijing-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AXT +9.9%; recommences substrate production at Beijing facility</a></h4><ul><li>Less than a week since an electrical fire (March 16) halted all substrate processing at its Beijing manufacturing plant, AXT (NASDAQ:<a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a>) <a href=\"https://seekingalpha.com/pr/16775160-axt-inc-resumes-substrate-production-beijing-manufacturing-facility\" target=\"_blank\">notes</a> wafer processing production is again operational.</li><li>A return to full production is projected for Q2.</li><li>Last week &ndash;&nbsp;<a href=\"https://seekingalpha.com/news/3251749-axt-minus-15_2-percent-fire-beijing-facility-impacts-manufacturing-production\" target=\"_blank\">AXT -15.2%, fire at Beijing facility impacts manufacturing production</a>&nbsp;(March 16) /&nbsp;<a href=\"https://seekingalpha.com/news/3251957-axt-minus-3-percent-pre-market-b-riley-and-co-downgrades-neutral\" target=\"_blank\">AXT -3% pre-market; B. Riley &amp; Co. downgrades to Neutral</a>&nbsp;(March 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252182\" data-linked=\"AXT +9.9%; recommences substrate production at Beijing facility\" data-tweet=\"$AXTI - AXT +9.9%; recommences substrate production at Beijing facility https://seekingalpha.com/news/3252182-axtplus-9_9-recommences-substrate-production-beijing-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3252182-axtplus-9_9-recommences-substrate-production-beijing-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252177\" data-ts=\"1490013642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252177-nektar-therapeutics-pain-candidate-nktrminus-181-successful-in-late-stage-study-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar Therapeutics&#39; pain candidate NKTR-181 successful in late-stage study; shares ahead 19% premarket</a></h4><ul><li>Nektar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a>) is up&nbsp;<font color='green'>19%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16775150-nktrminus-181-meets-primary-secondary-endpoints-phase-3-summitminus-07-study-chronic-pain\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, SUMMIT-07, evaluating opioid analgesic candidate NKTR-181 for the treatment of patients with chronic low back pain. The trial met its primary endpoint of showing statistically valid improved pain relief compared to placebo (p=0.0019). Secondary endpoints were also met.</li><li>The company says Fast Track-tagged NKTR-181, a full mu-opioid agonist molecule, is designed to provided potent pain relief without the high levels of euphoria that can lead to abuse and addiction. In a human abuse potential study the highest analgesic dose of NKTR-181 was barely distinguishable from placebo in terms of drug-liking and euphoria.</li><li>Management will host a conference call at 8:45 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252177\" data-linked=\"Nektar Therapeutics&#39; pain candidate NKTR-181 successful in late-stage study; shares ahead 19% premarket\" data-tweet=\"$NKTR - Nektar Therapeutics&#39; pain candidate NKTR-181 successful in late-stage study; shares ahead 19% premarket https://seekingalpha.com/news/3252177-nektar-therapeutics-pain-candidate-nktrminus-181-successful-in-late-stage-study-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3252177-nektar-therapeutics-pain-candidate-nktrminus-181-successful-in-late-stage-study-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252176\" data-ts=\"1490013482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252176-monness-crespi-hardt-co-initiates-snap-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monness, Crespi, Hardt &amp; Co. initiates Snap at Buy</a></h4><ul><li>Issuing the first bullish sell-side rating on Snap, <a href=\"http://www.cnbc.com/2017/03/20/wall-street-grants-snapchat-its-first-buy-rating-shares-rise.html\" target=\"_blank\">analyst James Cakmak</a> notes firm may be granting excessive credit for unproven business-building abilities, opposed to only a product, though observes \"more to Snap than many suggest.\" Price target $25.</li><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) $19.90,&nbsp;<font color='green'>+1.84%</font>&nbsp;pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252176\" data-linked=\"Monness, Crespi, Hardt &amp; Co. initiates Snap at Buy\" data-tweet=\"$SNAP - Monness, Crespi, Hardt &amp; Co. initiates Snap at Buy https://seekingalpha.com/news/3252176-monness-crespi-hardt-co-initiates-snap-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3252176-monness-crespi-hardt-co-initiates-snap-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252165\" data-ts=\"1490012077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FEYE\" target=\"_blank\">FEYE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252165-fireeye-upgraded-buy-bofa-merrill-chance-for-upside-surprise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FireEye upgraded at Buy at BofA Merrill with chance for upside surprise</a></h4><ul>     <li>FireEye (NASDAQ:<a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a>) <font color='green'>+6.2%</font> premarket after BofA Merrill Lynch <a href=\"https://www.streetinsider.com/Analyst+Comments/BofAMerrill+Lynch+Upgrades+FireEye%2C+Inc+%28FEYE%29+to+Buy%2C+%22Eyeing+A+Turnaround%22/12684921.html\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with an $18 price target, raised from $13.50, saying Wall Street largely ignores the company's guidance for growth resumption in H2 2017, which offers an opportunity for a positive surprise.</li>     <li>BofA believes&nbsp;FEYE&rsquo;s core value proposition is centered around having some of the most advanced threat intelligence that lends its value to three areas of  innovation: dealing with network threats, strong position in endpoint protection, and the value of analytics and threat management.</li><li>The firm sees three key drivers for growth, serving as potential catalysts for the stock - 6K appliances that are due a refresh, representing $200M of market opportunity; new products (cloud MVX, Smart grid, Helix, enhancements to FireEye-as-a-Service and the next gen endpoints); improvements to its go-to-market, adding new sales leadership, removing sales capacity constraints, and reducing the channel partner conflict.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252165\" data-linked=\"FireEye upgraded at Buy at BofA Merrill with chance for upside surprise\" data-tweet=\"$FEYE - FireEye upgraded at Buy at BofA Merrill with chance for upside surprise https://seekingalpha.com/news/3252165-fireeye-upgraded-buy-bofa-merrill-chance-for-upside-surprise?source=tweet\" data-url=\"https://seekingalpha.com/news/3252165-fireeye-upgraded-buy-bofa-merrill-chance-for-upside-surprise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252163\" data-ts=\"1490012051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMBA\" target=\"_blank\">JMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252163-jamba-down-3-on-lower-comp-sales-and-10k-filing-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jamba down 3% on lower comp sales and 10K filing delay</a></h4><ul> <li>Jamba (NASDAQ:<a href='https://seekingalpha.com/symbol/JMBA' title='Jamba, Inc.'>JMBA</a>) <a href=\"https://seekingalpha.com/pr/16775115-jamba-inc-provides-fiscal-year-2016-update-2017-outlook\" target=\"_blank\">announced</a> delay in completing       the Company&rsquo;s 10K.</li><li>Q4 Comparable-store sales declined 2.5%.</li>     <li>The company expects total revenue for FY'16 to meet or exceed $78M and Non-GAAP adjusted EBITDA to meet or exceed $10.5M.</li>     <li>&ldquo;During the       year we exited a number of non-core businesses and focused on energizing       the brand while also driving sales and profitability. I expect these       efforts to drive continued results and look forward to a successful 2017       and beyond,\" said Dave       Pace, President and CEO.</li><li><strong>FY2017 Guidance</strong>: Total revenue: $75M -77M; Annual system-wide comparable sales: flat, to slightly positive; Non-GAAP Adjusted G&amp;A expense: ~$21M; Non-GAAP Adjusted EBITDA: $13M-15M.<img src=\"http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170320005431r1&amp;sid=acqr7&amp;distro=nx&amp;lang=en\" alt=\"http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170320005431r1&amp;sid=acqr7&amp;distro=nx&amp;lang=en\"  /></li>                                       <li>JMBA&nbsp;<font color='red'>-3.03%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252163\" data-linked=\"Jamba down 3% on lower comp sales and 10K filing delay\" data-tweet=\"$JMBA - Jamba down 3% on lower comp sales and 10K filing delay https://seekingalpha.com/news/3252163-jamba-down-3-on-lower-comp-sales-and-10k-filing-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3252163-jamba-down-3-on-lower-comp-sales-and-10k-filing-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252160\" data-ts=\"1490011775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTMX\" target=\"_blank\">CTMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252160-cytomx-up-33-premarket-on-expanded-partnership-bristol-myers-squibb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytomX up 33% premarket on expanded partnership with Bristol-Myers Squibb</a></h4><ul><li>Thinly traded micro cap CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a>) jumps&nbsp;<font color='green'>33%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16775093-bristol-myers-squibb-cytomx-therapeutics-extend-worldwide-collaboration-discover-probody\" target=\"_blank\">announcement </a>that it has expanded its strategic collaboration with Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>), originally inked in 2014, to include eight additional targets using CytomX's Probody platform. BMY has selected four oncology targets so far, including CTLA-4.</li><li>Under the terms of the new agreement, CytomX will receive an upfront payment of $200M, research funding, up to $448M in milestones and tiered mid-single-to-low-double-digit royalties on net sales of commercialized products.</li><li>CytomX says Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.&nbsp;By remaining inactive until they are activated by proteases in the tumor microenvironment,&nbsp;Probody therapeutics&nbsp;bind selectively to cells within tumor tissue with reduced binding to healthy tissue, potentially improving or creating a therapeutic window. Probody therapeutics may also have application in other diseases where proteases are dysregulated in affected tissues.</li><li>Previously: <a href=\"https://seekingalpha.com/news/1771153-bristol-myers-inks-two-collaboration-deals\" target=\"_blank\">Bristol-Myers inks two collaboration deals</a> (May 27, 2014)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252160\" data-linked=\"CytomX up 33% premarket on expanded partnership with Bristol-Myers Squibb\" data-tweet=\"$CTMX $CTMX $BMY - CytomX up 33% premarket on expanded partnership with Bristol-Myers Squibb https://seekingalpha.com/news/3252160-cytomx-up-33-premarket-on-expanded-partnership-bristol-myers-squibb?source=tweet\" data-url=\"https://seekingalpha.com/news/3252160-cytomx-up-33-premarket-on-expanded-partnership-bristol-myers-squibb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252157\" data-ts=\"1490011231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIF\" target=\"_blank\">TIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252157-tiffany-rises-on-william-blair-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tiffany rises on William Blair upgrade</a></h4><ul><li>The luxury goods retailer was <a href=\"http://thefly.com/landingPageNews.php?id=2522196&amp;headline=TIF-Tiffany-rating-change-\" target=\"_blank\">raised</a> to Outperform from Market Perform at William Blair.</li><li>The report said Tiffany's (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>) business has become more stable and that the stock may benefit from easier comparisons.</li><li>TIF <font color='green'>+2.5%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3252157\" data-linked=\"Tiffany rises on William Blair upgrade\" data-tweet=\"$TIF - Tiffany rises on William Blair upgrade https://seekingalpha.com/news/3252157-tiffany-rises-on-william-blair-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3252157-tiffany-rises-on-william-blair-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252156\" data-ts=\"1490010756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252156-array-bio-withdraws-u-s-marketing-application-for-binimetinib-for-rare-type-of-melanoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array Bio withdraws its U.S. marketing application for binimetinib for rare type of melanoma; shares off 13% premarket</a></h4><ul><li>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) slumps&nbsp;<font color='red'>13%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16774966-array-biopharma-provides-nemo-update\" target=\"_blank\">announcement </a>that it has withdrawn its New Drug Application &#40;NDA&#41; in the U.S. seeking approval of binimetinib for the treatment of NRAS mutation-positive melanoma, a rare subtype of skin cancer. The company's decision was based on feedback from the FDA that concluded that data from the Phase 3 NEMO study was not sufficient to demonstrate a clinical benefit.</li><li>The company says development will continue. The Phase 3 COLUMBUS trial, evaluating the combination of binimetinib and&nbsp;<a href=\"http://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/\" target=\"_blank\">encorafenib</a>&nbsp;for the treatment of BRAF-positive melanoma, remains on track for mid-year.</li><li><a href=\"http://www.arraybiopharma.com/product-pipeline/binimetinib/\" target=\"_blank\">Binimetinib&nbsp;</a>inhibits a protein kinase enzyme called MEK, which plays a key role in a cellular signaling pathway that is over-activated in certain cancers, especially those that express the mutations BRAF, KRAS and NRAS. Array licensed binimetinib to Novartis in 2010 but reacquired the rights after Novartis purchased GlaxoSmithKline's oncology business in early 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252156\" data-linked=\"Array Bio withdraws its U.S. marketing application for binimetinib for rare type of melanoma; shares off 13% premarket\" data-tweet=\"$ARRY - Array Bio withdraws its U.S. marketing application for binimetinib for rare type of melanoma; shares off 13% premarket https://seekingalpha.com/news/3252156-array-bio-withdraws-u-s-marketing-application-for-binimetinib-for-rare-type-of-melanoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3252156-array-bio-withdraws-u-s-marketing-application-for-binimetinib-for-rare-type-of-melanoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252153\" data-ts=\"1490010506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXLG\" target=\"_blank\">DXLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252153-on-destination-xl-groups-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Destination XL Group&#39;s Q4</a></h4><ul>     <li>Destination XL Group (NASDAQ:<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a>) reports comparable-store sales fell 2.4% in <a href=\"https://seekingalpha.com/pr/16775107-destination-xl-group-inc-reports-fourth-quarter-fiscal-2016-financial-results\" target=\"_blank\">Q4</a>.</li>     <li>DXL retail stores comp declined 1.9% during the quarter.</li>     <li>Gross margin rate slipped 90 bps to 44.9%.</li>     <li>Merchandise margins down 40 bps Y/Y due to an increase in promotional strategies over the peak December selling weeks.</li>     <li>SG&amp;A expense rate improved 390 bps to 36.1% primarily due to decreases in advertising costs and incentive accruals.</li>     <li>EBITDA grew 48.2% to $10.8M.</li>     <li>Inventories -6.1% to $117.45M.</li>     <li>Store count -2 Y/Y to 343.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Total sales:&nbsp;$470M to $480M; Total comp sales: +1% to +4%; Gross margin rate: ~46%; EBITDA: $24M to $30M; GAAP EPS:-$0.11 to -$0.23; Non-GAAP EPS: -$0.06 to -$0.14; Capex: ~$22M; Cash flow from operating activities: $37M to $42M; Store count: 344.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252153\" data-linked=\"More on Destination XL Group&#39;s Q4\" data-tweet=\"$DXLG - More on Destination XL Group&#39;s Q4 https://seekingalpha.com/news/3252153-on-destination-xl-groups-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3252153-on-destination-xl-groups-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252148\" data-ts=\"1490008948\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOV\" target=\"_blank\">MOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252148-movado-lower-on-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Movado lower on earnings miss</a></h4><ul>     <li>Movado (NYSE:<a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a>) reports net sales declined 7.5%&nbsp;on a constant currency basis in <a href=\"https://seekingalpha.com/pr/16775083-movado-group-inc-announces-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Q4</a>.</li>     <li>Gross margin rate squeezed 300 bps to 49.5% primarily driven by an unfavorable shift in channel and product mix.</li>     <li>Operating margin rate fell 240 bps to 5.7%.</li>     <li>Inventory -5.7% Y/Y to $153.17M.</li>     <li><b>FY2018 Guidance</b>: Net sales: $515M to $530M; Operating income: ~$50M to $55M; Tax rate: 32%; Net income: ~$33M to $36.3M; Diluted EPS: $1.40 to $1.55.</li>     <li>MOV&nbsp;<font color='red'>-6.99%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252148\" data-linked=\"Movado lower on earnings miss\" data-tweet=\"$MOV - Movado lower on earnings miss https://seekingalpha.com/news/3252148-movado-lower-on-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3252148-movado-lower-on-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252113\" data-ts=\"1489993060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABS\" target=\"_blank\">ABS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252113-albertsons-considers-merger-sprouts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albertsons considers merger with Sprouts</a></h4><ul><li>Insider trading? Albertsons (NYSE:<a href='https://seekingalpha.com/symbol/ABS' title='Albertsons Companies'>ABS</a>) has held preliminary takeover talks with Sprouts Farmers Market (NASDAQ:<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a>), <a href=\"https://www.bloomberg.com/news/articles/2017-03-19/cerberus-backed-albertsons-said-to-consider-merger-with-sprouts\" target=\"_blank\">Bloomberg reports</a>, after the latter <font color='green'>surged over 23%</font> last week, recording the best weekly gain since its IPO in 2013.</li><li>The talks involve a plan to take organic grocer Sprouts private and add it to Albertsons' portfolio, which includes eponymous grocery stores and the Safeway brand.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252113\" data-linked=\"Albertsons considers merger with Sprouts\" data-tweet=\"$ABS $ABS $SFM - Albertsons considers merger with Sprouts https://seekingalpha.com/news/3252113-albertsons-considers-merger-sprouts?source=tweet\" data-url=\"https://seekingalpha.com/news/3252113-albertsons-considers-merger-sprouts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":52,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}